Chemotherapy & Biotherapy Congress 2016 Presentation


Articles of Interest

Download zip

Files / Folders File Size Posted By Date Posted Actions
Fosaprepitant: “The Good” – Antiemetic; “The Bad”- Hypersensitivity; “The Ugly”-
23k SethEisenberg 8/30/16  
NTR FG Goals 4 12.pdf
ONS Nutrition Focus Group
61k SethEisenberg 4/19/12  
Syllabus Slides.8.2011 .FINAL.ppsx
2011 IOL Powerpoint presentation on Chemotherapy
2032k SethEisenberg 11/29/11  
Infusion Reactions (Vogel 2010).pdf
CJON OnLine Exclusive
230k SethEisenberg 4/13/10  
Trastuzumab-Induced Cardiotoxicity (5MI).pdf
Five Minute Inservice version of ONF article
173k SethEisenberg 12/9/09  
Prevent Extravasation Injury With the Use of Antidotes.pdf
From Vesicant Chemotherapy Extravasation Antidotes and Treatments by Lisa Schulmeister, RN, MN, APRN-BC,OCN®, FAAN. CJON August 2009.
166k SethEisenberg 9/1/09  


Gathering Momentum Towards Safer Work Environments: The Role of the Nurse and Pharmacist in Improving the Practice of Safe Handling of Hazardous Drugs - Webinar by Martha Polovich, PhD, RN, AOCN - Chemotherapy & Biotherapy Community Ex-Officio

You will have to register to access the program - but there is no cost.


New OSHA Guidance on Hazardous Drug Safe Handling

Posted by ONS Staff 5/1/16




Oral Chemo Guide

Oral Chemo Guide

Related Links

CHE SIG Celebrates 25th Anniversary in 2014

The Chemotherapy & Biotherapy SIG will be celebrating their 25th Anniversary in 2014. The CHE SIG and Biotherapy SIG (separate at the beginning) were approved in August of 1989 with 42/CHE SIG charter members and 55/BIO SIG charter members. There have been many CHE/BIO SIG leaders who contributed to our history:

Chemotherapy SIG
Sara Carter RN
Pamela Kennedy RN
Maryanne Fishman RN MS AOCN®
Mervianna Thompson RN BN MSN ANP
Jeannie VanderKruik BA RN BSN OCN®
Christina (Garda) White RN OCN®
Kathy Wilkinson RN BSN OCN®
Jeanne Held-Warmkessel MSN RN AOCN® AOCNS-BC
Seth Eisenberg RN ASN OCN®
Mildred Toth RN MS AOCN®
Myra Davis-Alston RN MSN/ED OCN CRNI
Martha Polovich PhD RN AOCN®
Biotherapy SIG
Jacquelyn Beauregard-Dillman BA BS RN
Janet Appelbaum RN MS
Eileen Sharp RN BSN
Nancy Moldawer RN MSN   
Janet DiJulio RN MSNDanielle Gale ND MSN AOCNP®   
Peggy Esper DNP(c) MSN ANP-BC AOCN®
Paula Muehlbauer RN MSN AOCNS®
Brenda Keith RN MN AOCNS®
Kristine Abueg RN MSN OCN® CBCN®

Names of Targeted Therapies Names of Targeted Therapies

The Names of Targeted Therapies Give Clues to How They Work

by Deborah Christensen RN, BSN, HNB-BC


I was reading through the program of my granddaughter's dance recital and noticed that there was not a single common name in the first three groups of young dancers. It was as if their parents purposefully decided to come up with the most unique names possible. There may have been some family significance in the names, but it was hard to tell without knowing the family. This is not the case with the family names of targeted cancer drugs. Each generic name gives information on the what, how, and where of each particular drug.

In contrast to traditional chemotherapeutic agents that affect rapidly dividing cells, targeted agents are more precise in the way they fight cancer. Presently, two main families of targeted therapies exist—monoclonal antibodies and small molecule inhibitors. The ending letters (stem) of the generic names are like surnames that tell what family the drug is from and how the drug works to kill cancer cells. Monoclonal antibodies end with the stem “-mab” and small molecule inhibitors end with the stem “-ib”. The “-mab” family of targeted therapies has three distinct methods for interfering with cancer cell growth.


  1. Attach to receptors on the outside of cells to prevent the receptors from interacting with signaling molecules (e.g., growth factor receptors and growth factor interaction)
  2. Deliver radioactive molecules or toxins to the inside of the cells through attachment to cellular receptors
  3. Activate the body’s natural immune response


The “-mab” family is used when receptor targets are overexpressed on the outside of cancer cells. Conversly, the “-ib” family targets processes within the cell and therefore must be small enough in molecular weight to enter the cell and interfere with proteins on both the inside and outside of the cell. Proteins that code for growth or inhibit growth are some of the targets of this small but powerful family of drugs.

The sub stem of the generic names of the “-mabs” identifies the source where the antibodies were generated or cloned. The three most common sources are:


  1. Chimeric human-mouse—drugs ending in “-ximab” (i.e., rituximab)
  2. Humanized mouse—drugs ending in “-zumab” (i.e., bevicizumab)
  3. Fully human—drugs ending in “-mumab” (i.e., ipilimumab)


Finally, both “-mabs” and “-ibs” contain an additional stem to describe the targeted therapies bullseye. For example, the “tu” in rituximab indicates the target is the tumor, the “ci” in bevicizumab designates the circulatory system, and the “li” in ipilimumab identifies the immune system target. Some of the intracellular targets for the “-ibs” include:


  1. Tyrosine kinase inhibition—sub stem “-tinib” (i.e., imatinib)
  2. Proteasome inhibition—“-zomib” (i.e., bortezomib)
  3. Clyclin-dependent kinase inhibition—“-ciclib” (i.e., seliciclib)


The prefix of the generic names and the drug market names are where researchers and pharmaceutical companies—like the parents of the young dancers—take creative liberty.

The development of targeted therapies is expected to accelerate as new targets are identified; as a result, oncology nurses will need to stay up to date on the new medications so they can educate their patients on the way these therapies work as well as the possible side effects of the medications. Unfortunately, many people may have the idea that there are few if any side effects associated with targeted therapy. Although side effects can be less than those of standard chemotherapy, targeted therapies also affect normal cells to some degree.

So how do nurses keep up on the new therapies? Recently, ONS merged two key special interest groups (SIGs) the Targeted and Biologic Therapies SIG and the Chemotherapy SIG. The new SIG is now called the Chemotherapy and Biotherapy SIG. Another resource I found especially helpful was an animated video titled Understanding Targeted Cancer Therapies presented by the National Institute of Health.  

Identifying the source, target, and mechanism of action by uncoding the generic names of targeted therapies is fun. It is a whole lot easier than trying to figure out how parents come up with clever names for their children.